Thursday, May 11, 2017 5:36:01 PM
Positive safety, tolerability and activity data through Cohort 3 of Phase 1 study of CLR 131 in multiple myeloma
Initiation of fourth cohort of Phase 1 study of CLR 131 in multiple myeloma
Initiation of NCI-supported Phase 2 clinical trial of CLR 131 in multiple myeloma and other hematologic malignancies
Consolidation of intellectual property portfolio for CLR 131 in multiple myeloma following license agreement with Wisconsin Alumni Research Foundation
Publication in Nature Reviews Clinical Oncology and presentation at Academic Surgical Congress, both regarding PDC platform
Additional intellectual property protection for CLR 131 in solid tumors in the US
Grant of US patent for CLR 124 in PET imaging
Additional US method of use patents for CLR 1501, CLR 1502 and an additional CLR 1401-boron-dipyrromethene analog for the detection of multiple cancer types
Japanese composition of matter patent for CLR 1501 and CLR 1502
Additional Japanese method of use patents granted for CLR 131 and CLR 125 in cancer stem cells
Appointment of John Friend as chief medical officer
Appointment of Doug Swirsky and Fred Driscoll to the Cellectar Board of Directors
“We continue to advance the clinical development of our lead product candidate, CLR 131, now in a fourth cohort of a Phase 1 trial for multiple myeloma, and an NCI-supported Phase 2 study in hematological malignancies. We have also successfully worked to enhance our intellectual property portfolio to protect the value in our pipeline,” said Jim Caruso, president and CEO of Cellectar Biosciences. “The additions to our management team and board underscore our commitment to progressing Cellectar strategically as we continue our clinical and preclinical development programs.”
Recent CLRB News
- Iopofosine I 131 Featured in Two Separate Presentations at 12th International Workshop on Waldenstrom’s Macroglobulinemia • GlobeNewswire Inc. • 08/26/2024 10:40:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/23/2024 09:15:38 PM
- Cellectar to Restate Previously Issued Financial Statements – Company Announces Receipt of Expected Delinquency Notification Letter from Nasdaq • GlobeNewswire Inc. • 08/23/2024 09:00:00 PM
- Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend] • Edgar (US Regulatory) • 08/14/2024 11:15:55 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 08/14/2024 09:00:27 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/13/2024 10:45:19 AM
- Cellectar Biosciences Reports Financial Results for Q2 2024 and Provides a Corporate Update • GlobeNewswire Inc. • 08/13/2024 10:40:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/09/2024 09:00:47 PM
- UPDATE -- Cellectar Biosciences to Announce Second Quarter Financial Results and Host a Conference Call on Tuesday, August 13, 2024 • GlobeNewswire Inc. • 08/08/2024 09:15:14 PM
- Cellectar Biosciences to Announce First Quarter Financial Results and Host a Conference Call on Tuesday, August 13, 2024 • GlobeNewswire Inc. • 08/08/2024 08:05:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 07/24/2024 04:15:06 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/23/2024 10:45:24 AM
- Cellectar Biosciences’ Iopofosine I 131 Exceeds Primary Endpoint in Waldenstrom’s Macroglobulinemia Pivotal Study with 78% of Major Response Patients Remaining Progression Free at 18 Months • GlobeNewswire Inc. • 07/23/2024 10:40:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/22/2024 10:45:16 AM
- Cellectar Biosciences Announces Exercise of Tranche B Warrants and Purchase of New Warrants for Approximately $19.4 million with the Potential to Raise Up to an Additional $73.3 Million • GlobeNewswire Inc. • 07/22/2024 10:40:00 AM
- Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend] • Edgar (US Regulatory) • 07/11/2024 09:37:40 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/11/2024 09:15:21 PM
- Cellectar Biosciences to Host Key Opinion Leader Event to Review the Full Results from Its CLOVER WaM Pivotal Trial and Waldenstrom’s Macroglobulinemia Market Landscape • GlobeNewswire Inc. • 06/27/2024 10:40:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/18/2024 09:04:49 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/18/2024 09:04:06 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/18/2024 09:03:28 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/18/2024 09:02:59 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/18/2024 09:01:59 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/18/2024 09:01:29 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/18/2024 09:00:17 PM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM